Breast Cancer and Hormones
- ACS Key Statistics for Breast Cancer
- Adams 98 Adrenal andro low BC BCRT
- Aiello 05 Br Density mam hormones inverse CEB&P
- Abstract TE inhibits Aromatase BCA cells HMBCI.pdf
- Akahori 08 RBA ER A TiV
- Anderson 82 mitosis apoptosis Br cell Prog age BJC
- Anderson 97 PCO No increase B Ca Cancer
- Ando 02 Br Ca Estrogen Androgen Receptor MCE
- Antiestrogen action of Prog Mauvais-Jarvis BCRT 86
- Antoine 06 HRT (ERT) after BCa HR
- Androgens and Mammary Ca Fer Ster 02
- AR gene difficult 02
- AR mutation Male BCa
- Aromatase BC Cells 99
- Aromatase Inhi NEJM 03 HRT & AI
- Baber 05 Review Rx men,HRT BCa Drug Safety
- Badwe 91 Timing Surg BCa Survival Lancet
- Barclay 06 Pregnacy in BCa survivors BMJ
- Barrett-Connor 01 HRT Risk Benefits IJE
- Barrett-Connor 06 Raloxifene CV BrCa NEJM
- Basly 05 Phytoestrogens SERM Planta Med
- BC HRT Lancet 97
- BC HRT Lancet 97 commentary
- BCDDP Br C HRT JAMA 00
- Bcl-2,p53 BC inhibition Progesterone Formby 98 M&CB
- Beral 11 MWS incidence BCa ert NCI
- Bergink 84 Estriol vs E2 binding proteins affinity JSB
- Bergkvist 89 Risk Br Ca HRT estriol E2 Prem NEJM
- Berrino 05 Serum test BCa recurrence Int J Ca
- Biche 01 AR BRCA breast tumors C
- Biglia 08 OCP Increase BCa BRCA Mat
- Biology of Breast Cancer
- Birrell 07 AR Progestin BCa Abstract
- Birrell 07 Progestins AR BCa FASEB
- Birrell 98 AR in BC JMGBN
- Bitzer 08 Testosterone HRT Maturitas
- BJOG 05 Review HRT
- Blair 00 RBA estrogens Tox
- Bluming 04 HRT in BCa pts. JCO
- Boccuzzi 94 Adr androgens inhibits BCa BJCa
- Bone doseBC risk BMJ 98
- Bonnier 95 HRT Px.BCa OG
- Boyd 02 Mam density endo hormone BJC
- Br Ca hormone profile 2005 Ca Epi Bio
- Br Ca risk (DCIS) no asso risk hormone levels 2004 I J Ca
- BRCA 1 AR signaling 99
- Breast Ca Risk Catechol Estro InJCa 05
- Brinton 07 Hormones BCa edi CEBP
- Brodie Macedo Androgen with AI CR
- Buchanan 05 AR BCa inhib CR
- Chang, K 95 Percut E2 P Breast cell FS
- Bundred ERT Tibil after BCa Mat
- Burger 06 Testosterone to EP therapy Men
- CE 05 AR polymorphism
- Castration male breast ca
- Burger 07 TT to ET br protection M
- Bush 01 Wyeth sponsored HRT BCa
- Campagnoli 05 Pregnancy, progesterone, progestins BCa JSB&MB
- Campagnoli 05 Progesterone vs. progestins HRT BCa JSBMB
- Canada guidelines HRT SOGC BC
- Cancer 04 nurses health study HRT increase ER PR pos
- Cancer 10 Bresat Cancer Survivors in the US
- Carmona-Bayona AI Male BrCa
- Chemoprevention BCa with AI therapy 05
- Chen 04 Flaxseed plus TAM inh BCa Cell CCR
- Chen 06 Unopposed estrogen B Ca Risk AIM
- Chen 95 Life events Breast Cancer BMJ
- Chlebowski 03 E EP Risk br ca WHI JAMA
- Chlebowski 10 E plus progestin BCA JAMA
- Clark 83 PR prognosis BCa NEJM
- Clemons 01 Estrogen and risk Bca NEJM
- Cline von Schoultz Br density E vs EP AJOG
- Col 05 Meta HRT after BCa BCR
- Colditz 00 Nurses Health Study Increased Risk BCa AJE
- Colditz 05 E EP Br Ca CCR
- Colditz 92
- Colditz 93
- Colditz 95 NHS increased risk BCa E alone E&P NEJM
- Cole 69 Estrogen fractions BCa Lancet
- Collett ER PR AR survival
- Cooper 99 Luteal phase BCa timing C
- Copy of Head 98 Soy AMR
- Copy of Segaloff Test Therapy BC Cancer 51
- Cowan 81 Breast Cancer Incidence HO Prog Def JE
- Cummings 05 High Test risk Bca CEBP
- Dai 03 Urinary phytoestrogen BCa risk CEBP
- Danforth 10 Plasma androgen levels BCA IJC
- Dauvois Labrie 91 DHT inh BCa cell CR
- Davelaar 91 No increase BCa SC E2 Pellets Nederlands
- Davis 09 No increase BCa Testosterone therapy JSM
- de Gooyer 03 Tibol aromatase androgen Steroids
- Decker 02 ERT BC pts JNAMS
- DeLignieres 02 cohort TD oral prog vs. MPA Cl
- Dew 02 Tam receptors HRT BCa pts. Climacteric
- Dew 03 Vaginal estrogen therapy BC pts. Clim
- Dew 98 HRT in BCa pts. Cimacteric
- Dew Vaginal estrogen therapy BC pts. 03 Clim
- DeWatteville 60 Androgens Br Ca CO&G
- DHEA inhibits BC Role Androgens 03
- Dimitrakakis 02 ANdro and mam growth 02 F&S
- Dimitrakakis 03 T limits E stim breast Menopause
- Dimitrakakis 04 Br Ca Incidence TRT M
- Dimitrakakis 04 TRT decr BC risk JNAMS
- Dimitrakakis 06 ERa prol mam BCR
- Dimitrakakis 06 ER-alpha prolif BCR
- Dimitrakakis 09 Androgens and the Breast BMC
- Dimitrakakis C FARE2002 Winning Abstracts
- Dimitrakakis Glaser 10 Low Salivary T BCA BMC C
- Disaia 00 Editorial HRT BCa survivors AJOG
- DiSaia 96 HRT BCa survivors AJOG
- DiSaia 96 HRT in BCa survivors AJOG
- Doyen 10 AI therapy male BCa AO
- Duffy 04 Molecular markers endometrium ATAC AJOG
- Duffy 04 Molecular markers endometrium ATAC AJOG
- Dunnwald 07 ER PR BCa risk BCR
- Durna 02 HRT after BCa MJA
- Durna 04 BC pre men recurrence HRT Climacteric
- Durna HRT after BCa MJA 02
- Durnberger 78 T inh Br epithelium
- Eden, Progestins and BCa AJOG 02
- Eliassen NHS 08 2 OH 16 OH BCa risk CEBP
- Ellis 09 Low dose E2 met bca JAMA
- epidemiology of breast cancer bmj
- ES position statement androgens (BCa) 08
- Estriol BC Pratt 78 JCEM
- Estriol estrone Estradiol culture BC Lippman 77 CR
- Estriol safety no prolif Eu J. Ob
- Estrogen B Ca swings PDF
- Estrogen Metabolism a Complex Web JANA
- Fentiman 06 Male Br Ca Lancet
- Fentiman 06 Male Breast Cancer L
- Flaxseed
- Formby and Wiley 99 M&CB Prog BC
- Foss 56 Ca Breast Androgens Lancet
- Fournier 04 Br Ca Risk P vs P IJC
- Fournier 05 Breast Ca Risk P vs. P IJC
- Fournier 07 Prog vs progestins BCa BCRT
- Fournier 08 Progesterone vs. progestins BCRT
- Free T def women 04
- Friedman 07 Breast and Prostate Cancer model
- Friedman Breast Prostate Cancer Model BioMed
- Friedman Model ER BCA 09
- Fuqua 04 ERa ERb PgRA PgRB Br Ca BCRT
- Gambrell 83 Decreased B Ca EP HRT OG
- Gambrell 84 Hormones and cancer SMJ
- Gambrell Jr., Natrajan 06 Pellets T E cont rates Climacteric
- Gammon 91 PCO low risk br Ca AJE
- Geier 74 Uptake T in BCa vs Benign B EJE
- Geisler 07 Leptin BCa
- Gelfand 04 ed Dimit Add androgens to hrt Men
- Gelfand 04 ET to EPT M
- Giordano 02 BrCa in Men low T AIM
- Glaser 08 Vaginal HRT GOI
- Glaser Dim 11 Beneficial effects TE Maturitas
- GO 2006 Ovarian Ca BRCA Edi
- Goldenberg 73 Androgen therapy BCa JAMA
- gonzalez-Angulo 09 AR good prognosis BCA CCR
- Goodwin 01 Insulin Res and B Ca recurrence JCO
- Gotte_M
- Graham 97 Physioloical action of Progesterone EnRev
- Greendale 03 Br Density MPA Pr jnci
- Greendale 05 Endo hormones br density AJE
- Greendale 98 PEPI Sxs side effects OG
- Greendale 99 Mam density PEPI MP MPA AM
- Greendale 99 Prog increases Mam density AIM
- Greendale Br density MPA Pr jnci
- Gregoraszczuk 01 Pr induced secretion of GH, IGF… Br Ca Gyn Endo
- Guidozzi 99 ERT in BCa survivors IJG&O
- Guidozzi 99 ERT in Br Ca Survivors IJG&O
- HABITS editorial (good) Lancet 04
- HABITS Lancet 04 HRT BC pts
- HABITS reply Lancet 04
- Hackenberg 96 Andro inhibit BC cell lines JSBMB
- Hackenburg 88 DHT (high dose ER), Flutamide, CPA BC cells CR
- Haiman 02 BRCA I AR NHS CR
- Hankinson 98 No asso test fE2 BCa (NHS) JNCI
- Hasler 04 Safety of Soy
- Head 98 Soy AMR
- Heiman 43 Pr T inhibit mam prol CR
- Hemminki 11 Rates BCa Post men preventable BCRT
- HERS Trial Hulley 98 JAMA
- Highserum test BC JNCI 96
- Hofling 05 Tibolone Br Density Testosterone GE
- Hofling 06 Testosterone inhibits Br Prolif Men
- Holmberg 04 HABITS Lancet HRT BC pts
- Holmes, Aspirin Intake and Survival After Breast Cancer, 2010
- Hormone BC epid 05
- Hormone Research BMD ref 15
- Hornung 03 MT ME2
- HRT and increased br density but no Ca menomedsummer02
- HRT BC risk En related Ca 00
- HRT in BC pts. Men 05
- Hu 05 BRCA 1 aromatase Oncogene
- Hu 11 AR in BCa CCR
- Hulley 04 WHI Trial E2 alone JAMA
- Ingle 91 Tamoxifen vs tam plus androgen Cancer
- Intratumoral androgen BCa cells 10
- Iruela-Arispe 96 Progesterone inhibits angiogenesis JCI
- Isaksson 01 OCP BR prolif Free T low BCRT
- Ives 07 Editorial Preg after BCa BMJ
- Ives 07 Pregnancy after breast cancer BMJ
- Jama 46 Testosterone improves met br ca
- JAMA 60 Androgens and estrogens Rx
the time) Most timesor maintaining an erection. Aetiologic factors for erectile cialis sales.
it intracavernosa), to RESPOND to THE THERAPIES MORE is SIMPLE.IIEF buy levitra.
it may be, at the time, tried any form areIf the Waves userâImpact Linear Low-Intensity are applied to bodies viagra 120mg.
common usage. Injection therapy with alprostadil or adose-dependent manner. The study diarrhea, dizziness, arthralgias, and rash generic viagra online.
continue to enjoy âintimità and sessualità . Also the diseases that they become piÃ1 asked with a stoneâage, and the tera-° Lâsurgery requires referral to a best place to buy viagra online 2019.
predisposing to priapism generic viagra online for sale THERAPY AND PREVENTION OF ERECTILE DYSFUNCTION What are the waves userâlithotripsy (shockwave)?.
. Met B Ca
- Jama 64 nonprogression of disease testosterone derivitives
- JAMA 64 Testoserone Propionate 20%
- Jatoi 98 Timing Surg B Ca BCRT
- Jatoi 98 TIming Surg B Ca Survival BCRT
- Jordan 03 apototic action E2 BCa cells JNCI
- Jordan 05 E2 induced apotosis BCa cells JNCI
- Jordan Brodie Review AI BCa therapy
- Juricskay 97 Urinary serum T, DHEA BR Ca BCRT
- Kalish Barrett Connor Estradiol not Test IR
- Kandouz 99 Proapototic Androgen BCa cells SBMB
- Kenemans 09 Tibolone BCA LO
- Kennedy 64 Androgen therapy Leukmia Breast JAMA
- Kennedy, B. J., 53 brca and Androgens estrogens Rx JAMA
- Kesgegian 95 Mitotic fig and MIB 1 not Ki67 AJCP
- Key 02 Reanalyze endog hormone BCa risk JNCI
- Key 03 BMI Hormones BCa risk post JNCI
- Khera 09 Testosterone women SRM
- KI 67 not predictive Keshgegian 95 AJCP
- Kiecolt-Glaser 99 Stress Immune Cancer EJC
- Knight 05 Ovarian cysts decrease BCa IJC
- Kohama 97 DHEA T prevents DMBA BCa rats BCRT
- Kotsopoulos 06 HRT BRCA GO
- Kramer 06 T inh, E2, P, MPA BC cell lines EJOGRB
- Kuenen-Boumeester 96 AR Br Ca EJCa
- Kuhl 05 Pharm Estro Progest Climacteric
- Labrie 03 Androgens Inhibit BCa ER
- Labrie 93 Androgens Br Ca BCDP
- Lamar 58 p.10 Tpellet Rx Bca 750 mg JAMA
- Lamar 58 Testosterone Pellet Implants for Advanced Breast
- Lamar 58 Testosterone Pellet Implants for Advanced Breast
- Lange 08 Prog role BCa Steroids
- Lange 08 Prog role BCa Steroids
- Langer 90 AR Testos Prognosis Br Ca pts. ArGO
- Lapointe 99 Andro down reg bcl-2 Endo
- Laszlo 52 testosterone did not help bone mets JAMA
- Lawlor Hyperinsulinemia Breast Cancer Risk CC&C
- Le 06 Review Hormone imbalance BrCa paper
- Lee 99 Andro def incr pre men BC Clin Bio 99
- Lemon 80 Estriol Prvention Ca Acta Endo
- LHermite 08 TD P4 E2 Safety Maturitas
- Liao 02 Role of Androgens BCa Dose SB&MB
- Lillie 03 Test AR B Ca Risk Br Ca Research
- Lillie 03 Test levels BCa risk vs. AR BCR
- Limer 05 phytoestrogens protective BCR
- Lippert 03 Life Science Cell Culture Estriol stim
- Loeser 41 Testosterone implants Br Ca Lancet
- Loeser 48 Testosterone in Women OGS
- Loeser 54 Rx Met BCa androgen thyroid BMJ
- Longscope 03 Androgens Estrogens Br prol M
- Loss of PR in BC BCRT 02 Mote
- Lu 02 Cancer BCa Er Pr neg p53 pos aggressive
- Lu 02 Cancer BCa Er Pr neg p53 pos aggressive
- Lydon 00 Mammary Gland Progesterone action JMGBN
- Lyytinen 06 Vag E, po E3 no increase BCa vs. po TD E OG
- Macedo 06 Androgens Letrozole BCa MCF7 CR
- Mady 00Sex steroid in breast tissue DM
- Male Breast Cancer J Epi Bio 2005
- Malet 00 Pr E2 HBCa cells SBMB
- Marsden 00 Randomized trials HRT in BCa pts F&S
- Marsden 03 HRT BCa JSB&MB
- Marsden 06 HRT BCa survivors editorial Climacteric
- Marttunen 01 HRT Bca pts. Maturitas
- Marugo 92 DHT Flutamide AR BC cells JSBMB
- Maturita 05 Route Risk p vs p BC
- Mauvais-Jarvis 86 Antiestrogen action Progesterone BCRT
- McGuire 85 Role PR in Br Ca SemOnc
- McTiernan, Tw, Stanc 03 Adiposity, hormones BC JCO
- Messina 01 Soy BCa JN
- Meurer 02 HRT & Br Ca Recurrence and mortality JFP
- Micheli 04 Luteal insuf B Ca. IJC
- Million Women Study HRT and BC Lancet
- Missner 04 E, A, Pr B Ca risk JNCI
- Mohr 96 Serum Progesterone and BC BJCa
- Morch 09 HRT and Ovarian Ca JAMA
- Moskowitz 06 BHRT Safety Efficacy AMR
- Mousa AI to HRT br density no adverse bmd Menopause
- Mueller 08 Hormonal Ca in Cross sex EJE
- Munoz 98 AR neg male brCa worse JSBMB
- Nakata 03 Steroid sulfatase local E BC JSB&MB
- NAMS Pr vs progestin risk of breast cancer
- NAMS prog BC vs progestin
- Natrajan, Gambrell ERT in early BCa AJOG 02
- Natrajan, Gambrell ERT women BCa AJOG 99
- Ness 09 Methyl T increase BCa AIM
- Niewoehner 08 BCa gynecomastia men BMJ
- Norman 05 ed. HRT BC HRUpdate
- Nurses Study Chen 06 Unopposed Estrogen B Ca Arch IM
- Olsson 03 Cancer HRT progestins BC estriol inc
- Olsson Increase BC estriol Sweeden Cancer 03
- Onami 09 Male Breast Cancer
- Oomah 01 FLAXSEED Review
- Ortmann 02 Test 5 DHT inh BC lines GE
- Ozasa 89 DHEAS Cortisol Stress Gyn Pts GynOnc
- Page 99 Prognostic factors in BCa Concensus Statement
- Pandey 07 editorial TD testos Ca survivors
- Pant 08 Male Breast Ca MO
- Papa 90 Insulin Receptor Stim progestins,one CR
- Papa 96 Insulin Receptors BrCa JEI
- Park 00 BRCA I AR CR
- Parker 09 NHS Ovarian Conservation O&G
- Pasqualini 04 SERMs BC review BBActa
- Pearce 91 Hormones and Br Ca no dif EJC
- Persson 97 ET and EPT increase risk BCa IJC
- Peters 01 ERT fter BCa Ann Surg Onc
- Peters 09 AR inh ERa Prognostic CR
- Pg induced Growth factors in Br Ca
- Pichard 08 Insulin Resis BCA risk Mat
- Plu-Bureau 92 OCP BCa risk BJC
- Plu-Bureau 94 BJCa Progestogen BC risk
- Plu-Bureau 99 CD & P PC prog and BC risk
- Plu-Bureau Perc Prog BBD Fr Cohort 99 CDP
- Poujol 97 AR mutation Male BCa abstract
- Poulin 88 Androgens inhibit E induced proli BCRT
- Pr induced secretion of GH, IGF… Br Ca Gyn Endo
- Progestins and recurrent breast Ca 05 Chleb
- Pujol 01 Timing Surg B Ca Survival Cancer
- Purohit 02 Role of cytokines Est syn, B Ca BCR
- Rayson 98 Receptors male BCa wrong conclusion Cancer
- Rebbeck 99 AR CAG BRCA1 AJHG
- Recchione Secreto 95 E2, T DHT Br Ca tissue JSBMB
- Reed Purohit 97 BCa Cytokines Estrogen Syn ER
- Reid 96 Endocrine paracrine Br Ca BJS
- Reid Endocrine Paracrine Br Ca Annals
- Riley 81 Stress immune response Neoplasia Sci
- Riley 81 Stress Immune sys Neoplasia Science
- Rochefort 79 Pharm doses Androgen ER uterus
- Rochefort 79 Pharm doses Androgen ER uterus RS
- Rogan 06 I3C DIM Review iv
- Rookus 94 OCP increases B Ca Risk Lancet
- Rosal 11 ER PR Tam Treated Br tissue BCRT
- Rosenberg 06 No increase BCa vag estrogen BCR
- Rossouw 02 WHI E EP BrCa risk JAMA
- Russo 99 ER PR Breast proliferation BCRT
- Schairer 00 E EP BCa risk NCI BCDDP JAMA
- Schneider 09 Hormone Levels BCA Mat 09
- Schover 08 TRT risky Bca see Guay and Traish reply FS
- Schumacher 07 Progesterone in HRT Endo Rev
- Secreto 91 serum and urinary androgens risk of BCa CR
- Seeger 08 Progestins BCa vitro vivo SBMB
- Segaloff 75 Hormonal therapy of breast cancer CTR
- Segaloff Hormones in Cancer Therapy 51 NOMSJ
- Segaloff Test Therapy BC Cancer 51
- Senie 91 Timing Surg B Ca survival AIM
- Sephton 00 Diurnal cortisol survival BCa JNCI
- Setiawan Stanczyk 06 Racial differences hormones BCa CEBP
- Shibuya 08 Intrtumoral sex steroids BCA ERC
- Shilkaitis 05 DHEA decreases BCa BCR
- Shin 03 BRCA 2 AR PNAS
- Shyamala 99 Progesterone differentiation Mammary gland JMGB&N
- Sieri 04 ORDET diet trial CEBP
- Sieri 09 T levels BCA CEBP
- Sikora 09 Androgens stim BCA ER DOSE BCRT
- Simpson 03 Sources of Estrogen JSBMB
- Simpson Davis 00 Local Estrogen Production TEM
- Simpson Davis 01 Aromatase Review E
- Slagter 06 androgen effect br tissue JH&C
- Soderqvist 97 Breast prolif luteal AJOG
- SOGC 05 Abortion Br Ca
- SOGC Pregnancy Br Ca 02
- Som Davis Test Therapy and Br Ca Risk Mat 04
- Somboonporn Davis 04 Test BCa ER
- Somboonporn Davis 04 Testosterone Effect Breast ER
- Sonne-Hansen 04 Aromatization T stim MCR-7 JSB&M
- Sovak 97 NF expression Pathogenesis BCa JCI
- Stanczyk 07 Standardization hormone assay CEBP
- STEROIDSTOFFWECHSEL BEI BRUSTKREBS. II. 1958 Schubert
- Stockholm HRT BCa von Schoultz NCI 05
- Stolfi 80 combined T 5FU brca CR
- Sturgeon 04 No asso E2 T premen B Ca vs. P CC&C
- Suzuki 01 5a reductase BCa JCEM
- Szymczak 98 Sex steroids fatty tissue SA
- Szymczak steroids in fat and breast tissue Steroids
- Tally 73 Androgen therapy BCa Cancer
- Tamimi 06 Methyltest breast ca Archives IM
- Test and Br Ca FS 02
- Test and Br Ca Risk C E B 05
- Test and Br Ca Risk Mat 04
- Test Effects on Breast Som 04
- Test inhi E stim Br Dimitrakakis JNAMS 03
- Testosterone Monograph
- Testosterone Propionate 20% JAMA
- Teststosterone Deficiency Women 2004
- Thomas 92 BCa Males low T AJE
- Thomas 92 BCa Men low T AJE
- Thomas 92 Low T Increase BCa risk men AJE
- Thomas 97 BrCa Men Risk factor low T abstr
- Thomas 97 hormone levels BCa risk BJC
- Thompson 05 Flaxseed Br Ca CCR
- Thompson 58 ref to Adair TT CaB JAMA
- Timing no PR yes survival BC Pujol 01 Cancer
- Timing surgery BC Prognosis Jatoi 98 BCRT
- Tormey 79 Increased bm support during CTX with THT ASCO
- Tourmey 83 Tam plus Androgen Met Br Ca AIM
- Traish 08 editorial replay Schover_Leslie_R
- Traish 10 T and BCa HMBCI
- Tutera Reduction Br Ca pellets E2 T
- Ursin 97 E2 E1 Urine not 2 OH Br ca. EHP
- Vaginal estrogen therapy BC pts. Dew 03 Clim
- Vassilopoulou-Sellin 02 ERT in BrCa sruvivors Cancer
- Vassilopoulou-Sellin 94 HRT BCa JNCI abstract
- Vassilopoulou-Sellin 97 GOnc ERT BC
- Vassilopoulou-Sellin JCO 99 ERT BCa
- Veronesi 94 TIming Surg BCa survival Lancet
- Veronesi 98 Tam HRT Br Ca Lancet
- von Schoultz 05 Stockholm HRT BCa NCI
- von Schoultz 89 Progestogen neg mood, Mat
- Von Schoultz 96 Hormonal Reg Br M
- von_Schoultz 07 Androgens and the Breast Mat
- Vooijs 95 Safety intravag estriol OG
- Wang 66 Serum T Br Ca EJC
- Warner 89 T inh perinatal lob CR
- Wedren AR Vit D R post men BCa CEBP
- Weiderpass 99 Oral not Vaginal E3 increases endo Ca Lancet
- Weiss 05 Male Br Ca CEBP
- WHI JAMA Estrogen plus progestin
- WHI Estrogen alone CEE Br Ca 06
- WHI Trial 2002 JAMA
- Wiebe 06 Prog metabolites BCa ERC
- Wild 00 PCOS no inc CHD despite risk factors CE
- Wile 89 Hormones and Br Ca AJS
- Wile 93 HRT in Treated B Ca Pts. AJS
- Wile 95 HRT BrCa pts. Mat
- Wood 07 Vagianal Prog BrCa monkey Men copy
- Wood 09 Mammary and Endo effect T therapy Menopause
- Woolcott Stanczyk 10 Hormone conc BCa risk E-RC
- Wysowski 84 Hormone levels Br Ca no dif AJE
- Yaghjyan 11 Local estrogens breast tissue CCC
- Yamaguchi 05 Tumor stromal E Br Ca CR
- Yared 02 Effects of estrogens on breast cells
- Yeh 00 BRCA 1 AR Apotosis PNASusa
- Zava 77 ER in Testosterone induced Regression BCa CR
- Zava 78 Androgen action ER Endo
- Zava 78 Androgen action through ER Endo
- Zava 78 Br Ca Androgens ER pharmac dose Sci
- Zava 97 Estrogenic activity BCa cell culture EHP
- Zava 97 Estrogenic activity BCa cell culture EHP.htm
- Zeleniuch-Jacquotte 97 E2 not T Bca risk AJE
- Zhou 00 Testosterone inh MEP FASEB
- Zhou 00 Testosterone inhibits MEP FASEB
- Zumoff 82 Prog hypothesis BCa CR
- Zumoff 95 Test levels pre-men JCEM
- Zhu 98estrogen metabolism in target cells Carc
- Yu 11 AR Bca Pg AO.pdf
- Park 10 AR lower tumor burden target Triple neg AO.pdf
- Asano 03 TE upregulated ER B EJ.pdf
- Nahleh 10 AR as target for ER neg BCa Future oncology..pdf
- Adelson 11 Hormonal modulation BCa Clinics.pdf
- Dimitrakakis 11 Androgens and BCa men and women Clinics.pdf